Living Biobank of Matched In Vitro & In Vivo Patient-Derived Models for Drug Development & Biomarker Identification

Time: 2:10 pm
day: Day Two


  • More clinically relevant models preserve the genetic and phenotypic characteristics of the original tumor, predict patient response, enabling improved cancer drug candidates to enter the clinic, and potentially overcome high oncology drug attrition rates
  • Early identification of biomarkers during preclinical drug development provides can provide additional benefits such as patient stratification, facilitating companion diagnostic clinical testing, and ultimately de-risking clinical trials